TissuPath publications and collaborations

2018

Heritable methylation marks associated with breast and prostate cancer risk. Dugué PA, Dowty JG, Joo JE, Wong EM, Makalic E, Schmidt DF, English DR, Hopper JL, Pedersen J, Severi G, MacInnis RJ, Milne RL, Giles GG, Southey MC. Prostate. 2018 Sep;78(13):962-969.
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP. Eur Urol. 2018 Nov;74(5):562-572.
Ga-labeled Prostate-Specific Membrane Antigen Ligand-Positron-Emission Tomography: Still Just the Tip of the Iceberg. Dundee P, Gross T, Moran D, Ryan A, Ballok Z, Peters J, Costello AJ. Urology. 2018 Jun 28. pii: S0090-4295(18)30619-8
Enduring epigenetic landmarks define the cancer microenvironment. Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, Chabanon RM, Qu W, Wang H, Richards M, Nair SS, Armstrong NJ, Nim HT, Papargiris M, Balanathan P, French H, Peters T, Norden S, Ryan A, Pedersen J, Kench J, Daly RJ, Horvath LG, Stricker P, Frydenberg M, Taylor RA, Stirzaker C, Risbridger GP, Clark SJ. Genome Res. 2018 May;28(5):625-638.
Xp11 translocation renal cell carcinoma paraneoplastic syndrome presenting as cutaneous vasculitis: first reported case of yet another mask. Pascoe C, Christidis D, Clouston D, Lawrentschuk N. BMJ Case Rep. 2018 Apr 21;2018.
The Use of CRISPR/Cas9 Gene Editing to Confirm Congenic Contaminations in Host-Pathogen Interaction Studies. Ferrand J, Croft NP, Pépin G, Diener KR, Wu D, Mangan NE, Pedersen J, Behlke MA, Hayball JD, Purcell AW, Ferrero RL, Gantier MP. Front Cell Infect Microbiol. 2018 Mar 19;8:87.
Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. McCart Reed AE, Kutasovic JR, Nones K, Saunus JM, Da Silva L, Newell F, Kazakoff S, Melville L, Jayanthan J, Vargas AC, Reid LE, Beesley J, Chen XQ, Patch AM, Clouston D, Porter A, Evans E, Pearson JV, Chenevix-Trench G, Cummings MC, Waddell N, Lakhani SR, Simpson PT. J Pathol. 2018 Apr;244(4):460-468.
Obtaining high quality transcriptome data from formalin-fixed, paraffin-embedded diagnostic prostate tumor specimens. FitzGerald LM, Jung CH, Wong EM, Joo JE, Gould JA, Vasic V, Bassett JK, O’Callaghan N, Nottle T, Pedersen J, Giles GG, Southey MC. Lab Invest. 2018 Apr;98(4):537-550.
Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Trpkov K, Athanazio D, Magi-Galluzzi C, Yilmaz H, Clouston D, Agaimy A, Williamson SR, Brimo F, Lopez JI, Ulamec M, Rioux-Leclercq N, Kassem M, Gupta N, Hartmann A, Leroy X, Bashir SA, Yilmaz A, Hes O. Histopathology. 2018 Apr;72(5):777-785
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. Porter LH, Hashimoto K, Lawrence MG, Pezaro C, Clouston D, Wang H, Papargiris M, Thorne H, Li J; kConFab, Ryan A, Norden S, Moon D, Bolton DM, Sengupta S, Frydenberg M, Murphy DG, Risbridger GP, Taylor RA. BJU Int. 2018 Jun;121(6):971-978.

2017

New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer. Wong LM, Chu K, Corcoran N, Norden S. Anticancer Agents Med Chem. 2017 Nov 13. doi: 10.2174/1871520617666171114105846. [Epub ahead of print]
3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk prediction. Hovens MC, Lo K, Kerger M, Pedersen J, Nottle T, Kurganovs N, Ryan A, Peters JS, Moon D, Costello AJ, Corcoran NM, Hong MKH. Pathol Res Pract. 2017 Dec;213(12):1523-1529.
Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study. Papa NP, MacInnis RJ, Jayasekara H, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG. Prostate Cancer Prostatic Dis. 2017 Sep;20(3):305-310.
Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG. Urol Oncol. 2017 Aug;35(8):530.e7-530.e13.
Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA. Eur Urol. 2017 Oct;72(4):492-495.
Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study. FitzGerald LM, Naeem H, Makalic E, Schmidt DF, Dowty JG, Joo JE, Jung CH, Bassett JK, Dugue PA, Chung J, Lonie A, Milne RL, Wong EM, Hopper JL, English DR, Severi G, Baglietto L, Pedersen J, Giles GG, Southey MC. Prostate. 2017 Apr;77(5):471-478.
Characterisation of microbial communities within aggressive prostate cancer tissues. Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J; Australian Prostate Cancer BioResource, Giles GG, Southey MC. Infect Agent Cancer. 2017 Jan 13;12:4.
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG. Nat Commun. 2017 Jan 9;8:13671.

2016

Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry – Victoria. Evans SM, Patabendi Bandarage V, Kronborg C, Earnest A, Millar J, Clouston D. Prostate Int. 2016 Dec;4(4):145-151.
Comparing nodal versus bony metastatic spread using tumour phylogenies. Mangiola S, Hong MK, Cmero M, Kurganovs N, Ryan A, Costello AJ, Corcoran NM, Macintyre G, Hovens CM. Sci Rep. 2016 Sep 22;6:33918.
Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years. Perera M, Lawrentschuk N, Perera N, Bolton D, Clouston D. Prostate Int. 2016;4 (1): 11-4.
Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study. Gannan E, Khoo J, Nightingale S, Suhardja TS, Lippey J, Keane H, Tan KJ, Clouston D, Gorelik A, Mann GB; Breast J. 2016;22 (4): 413-9.
High-Resolution Map of Somatic Peri-Prostatic Nerves. Reeves F, Battye S, Borin JF, Corcoran NM, Costello AJ. Urology. 2016 Nov;97:160-165
The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L,Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L. Clin Cancer Res. 2016 Nov 15;22(22):5539-5552.
Routinely reported ‘equivocal’ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. Galiabovitch E, Hovens CM, Peters JS, Costello AJ, Battye S, Norden S, Ryan A, Corcoran NM. BJU Int. 2017 Apr;119(4):567-572.
Keystone Island Flap: Effects of Islanding on Vascularity. Lo CH, Nottle T, Mills J. Plast Reconstr Surg Glob Open. 2016;4 (2): e617.
Validation of the novel ISUP-2014 5-tier Gleason grade grouping: Biochemical recurrence rates of 3+5 disease may be overestimated. van den Bergh RC, van der Kwast TH, de Jong J, Zargar H, Ryan AJ, Costello AJ, Murphy DG, van der Poel HG. BJU Int. 2016 Oct;118(4):502-5.
Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer. Hunter SM, Rowley SM, Clouston D; KCon Fab Investigators, Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H. Urol. Oncol. 2016;34 (3): 120.e9-16.
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Li J, Meeks H, Feng BJ, Healey S, Thorne H, Makunin I, Ellis J; kConFab Investigators, Campbell I, Southey M,Mitchell G, Clouston D, Kirk J, Goldgar D, Chenevix-Trench G. J. Med. Genet. 2015;53 (1): 34-42.
Subungual fibro-osseous pseudotumour of the toe. Meani RE, Bloom RJ, Battye S, Chamberlain AJ. Australas. J. Dermatol. 2016;57 (2): e57-60.

2015

Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy. Toner L, Weerakoon M, Bolton DM, Ryan A, Katelaris N, Lawrentschuk N. Prostate Int. 2015;3 (4): 107-14.
The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis. Pearson HB, McGlinn E, Phesse TJ, Schlüter H, Srikumar A, Gödde NJ, Woelwer CB, Ryan A, Phillips WA, Ernst M, Kaur P, Humbert P. Mol. Cancer. 2015;14 (1): 169.
Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. Lawrence MG, Pook DW, Wang H, Porter LH, Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A, Norden S, Papargiris MM, Risbridger GP, Taylor RA.Prostate. 2015;75 (13): 1475-83.
Predictors of prostate cancer-specific mortality after radical prostatectomy: 10-year oncologic outcomes from the Victorian Radical Prostatectomy Registry. Bolton DM, Papa N, Ta AD, Millar J, Davidson AJ, Pedersen J, Syme R, Patel MI, Giles GG. BJU Int. 2015;116 Suppl 3: 66-72.
Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. Reeves F, Hovens CM, Harewood L, Battye S, Peters JS, Costello AJ, Corcoran NM. Can Urol Assoc J. 2015;9 (5-6): E252-5.
Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions. Chang JH, Lim Joon D, Davis ID, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Bolton D, Scott AM, Khoo V. Int. J. Radiat. Oncol. Biol. Phys. 2015;92 (2): 438-45.
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM. Nat Commun. 2015;6: 6605.
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R,Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L. Oncotarget. 2015;6 (2): 604-16.
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM. Eur. Urol. 2015;67 (3): 496-503.
Altered significance of D’Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. Bolton D, Cheng Y, Willems-Jones AJ, Li J, Niedermeyr E, Mitchell G, Clouston D, Lawrentschuk N, Sliwinski A, Fox S, Thorne H. BJU Int. 2015;116 (2): 207-12.

2014

A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease. Severi G, FitzGerald LM, Muller DC, Pedersen J, Longano A, Southey MC, Hopper JL, English DR, Giles GG, Mills J. Cancer Med. 2014;3 (5): 1266-74.
Detection of infectious organisms in archival prostate cancer tissues. Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Longano A, Garland SM, Southey MC, Giles GG¹. BMC Cancer. 2014;14 (1): 579.
A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan G,Risbridger GP.J. Pathol. 2014;234 (1): 86-98.
Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology. Styles C, Ferris N, Mitchell C, Murphy D, Frydenberg M, Mills J, Pedersen J, Bergen N, Duchesne G. J Med Imaging Radiat Oncol. 2014;58 (4): 439-48.
Comparison contemporary methods of estimating prostate tumor volume in pathological specimens. BJU Int. 2014 Mar; 113 Suppl 2:29-34.
Diffusion-weighted MRI, (11)C-choline PET and (18)F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Tochon-Danguy H, Chan JG, Bolton D, Scott AM, Khoo V, Davis ID. Eur Radiol. Epub 2013 Nov 6
Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer. Fankhauser M, Tan Y, Macintyre G, Haviv I, Hong MK, Nguyen A, Pedersen JS, Costello AJ, Hovens CM,Corcoran NM. Clin. Cancer Res. 2014;20 (21): 5547-57.
Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, et al. Ann Diagn Pathol. 2014;18 (6): 333-42.
Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, Hovens CM, Macintyre G. BMC Genomics. 2014;15 (1): 51.

2013

Bladder cancer biorepositories in the “-omics” era: integrating quality tissue specimens with comprehensive clinical annotation. Sapre N, Hong MK, Huang JG, Pedersen J, Ryan A, Anderson P, Costello AJ, Corcoran NM, Hovens CM. Biopreserv Biobank. 2013;11 (3): 166-72.
Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate. 2013;73 (16): 1810-23. Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP, Taylor RA.
Metaplastic conditions of the bladder. BJU Int. 2013;112 Suppl 2: 27-31. Clouston D, Lawrentschuk N.
Diffusion-weighted MRI, (11)C-choline PET and (18)F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol 2013 Nov 6. [Epub ahead of print]. Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, O’Sullivan R, Goh YP, Tochon-Danguy H, Chan JG, Bolton D, Scott AM, Khoo V, Davis ID.
Extraprostatic Extension into Periprostatic Fat is a More Important Determinant of Prostate Cancer Recurrence than an Invasive Phenotype. J. Urol. 2013;190 (6): 2061-7. Kapoor J, Namdarian B, Pedersen J, Hovens C, Moon D, Peters J, Costello AJ, Ruljancich P, Corcoran NM.
Comparison contemporary methods of estimating prostate tumor volume in pathological specimens. BJU Int. 2013; . Perera M, Lawrentschuk N, Bolton D, Closton D.
Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clin. Exp. Metastasis – epub Oct 2. Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM.
A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. Sci Transl Med. 2013;5 (187): 187ra71. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.
A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc. 2013;8 (5): 836-48. Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B,Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.
Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. BJU Int. 2013;111 (6): 921-7. Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials. 2013;34 (20): 4777-85. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW; Australian Prostate Cancer BioResource, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP.
Primary culture and propagation of human prostate epithelial cells. Methods Mol. Biol. 2013;945: 365-82. Niranjan B, Lawrence MG, Papargiris MM, Richards MG, Hussain S, Frydenberg M, Pedersen J, Taylor RA, Risbridger GP.
Error rates in a clinical data repository: lessons from the transition to electronic data transfer – a descriptive study. Hong MK, Yao HH, Pedersen JS, Peters JS, Costello AJ, Murphy DG, Hovens CM, Corcoran NM. BMJ Open. 2013;3 (5)

2012

Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer. BJU Int. 2012;110 Suppl 4: 58-63. Sapre N, Pedersen J, Hong MK, Harewood L, Peters J, Costello AJ, Hovens CM, Corcoran NM.
Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer. Pathology. 2012;44 (6): 513-8. Mills J, Oliver A, Sherwin JC et-al. Mills J, Oliver A, Sherwin JC, Frydenberg M, Peters JS, Costello A, Harewood L, Love C, Redgrave N, van Golen KL, Bailey M, Pedersen J.
Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology. 2012;44 (3): 204-8. Kerger M, Hong MK, Pedersen J, Nottle T, Ryan A, Mills J, Peters JS, Moon D, Crowe H, Costello AJ, Corcoran NM, Hovens CM.
Prostate weight is the preferred measure of prostate size in radical prostatectomy cohorts. BJU Int. 2012;109 Suppl 3: 57-63. Hong MK, Yao HH, Rzetelski-West K, Namdarian B, Pedersen J, Peters JS, Hovens CM, Corcoran NM.
Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology. 2011;43 (2): 138-42. Hong MK, Namdarian B, Corcoran NM, Pedersen J, Murphy DG, Peters JS, Harewood L, Sapre N, Rzetelski-West K, Costello AJ, Hovens CM.
Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. British Journal of Urology International – in press (2012). Corcoran NM, Hovens CM, Metcalfe C, Hong MK, Pedersen J, Casey RG, Peters J, Harewood L, Goldenberg SL, Costello AJ, Gleave ME.

2011

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. British Journal of Urology International (2011). Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL. http://www.ncbi.nlm.nih.gov/pubmed/22085203
Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. British Journal Urology International (2011). Corcoran NM, Hovens CM, Hong MK, Pedersen J, Casey RG, Connolly S, Peters J, Harewood L, Gleave ME, Goldenberg SL, Costello AJ – http://www.ncbi.nlm.nih.gov/pubmed/21895937
Immunohistochemical study of the cavernous nerves in the periprostatic region. British Journal of Urology International (2011). Costello AJ, Dowdle BW, Namdarian B, Pedersen J, Murphy DG. http://www.ncbi.nlm.nih.gov/pubmed/20942832
Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup.Pathology (2011). Hong MK, Namdarian B, Corcoran NM, Pedersen J, Murphy DG, Peters JS, Harewood L, Sapre N, Rzetelski-West K, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/21233675
Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers. Urologic Oncology (2011). Namdarian B, Wong E, Galea R, Pedersen J, Chin X, Speirs R, Humbert PO, Costello AJ, Corcoran NM, Hovens CM – – http://www.ncbi.nlm.nih.gov/pubmed/21549621
A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. Journal of Urology (2011). O’Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J. http://www.ncbi.nlm.nih.gov/pubmed?term=ryan%20mills%20nomogram
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation (2011). Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, Tuveson DA, Simon R, Humbert PO – http://www.ncbi.nlm.nih.gov/pubmed/21965329
Improved detection of mycobacteria species in formalin-fixed tissue sections. Histopathology (2011). Pedersen JS, Clarke I, Mills J. http://www.ncbi.nlm.nih.gov/pubmed/22092411
Brief report: a bioassay to identify primary human prostate cancer repopulating cells. Stem Cells (2011). Toivanen R, Berman DM, Wang H, Pedersen J, Frydenberg M, Meeker AK, Ellem SJ, Risbridger GP, Taylor RA. – http://www.ncbi.nlm.nih.gov/pubmed/21674698

2010

Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urologic Oncology (2010). Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, Mete U, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/19162513
Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study. British Journal of Cancer (2010). Severi G, Shannon BA, Hoang HN, Baglietto L, English DR, Hopper JL, Pedersen J, Southey MC, Sinclair R, Cohen RJ, Giles GG – http://www.ncbi.nlm.nih.gov/pubmed/20606679
Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. Journal of Urology (2010). Sherwin JC, Mirmilstein G, Pedersen J, Lawrentschuk N, Bolton D, Mills J – http://www.ncbi.nlm.nih.gov/pubmed/20303103

2000-2009

Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer (2009). Balanathan P, Williams ED, Wang H, Pedersen JS, Horvath LG, Achen MG, Stacker SA, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/19436293
Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint.
British Journal of Urology International (2008). Bruyere F, Corcoran NM, Berdjis N, Namdarian B, Pedersen J, Ockrim J, Voelzke BB, Costello AJ, Hovens CM – http://www.ncbi.nlm.nih.gov/pubmed/18341621
Early-onset endocrine disruptor-induced prostatitis in the rat. Environmental Health Perspectives (2008). Cowin PA, Foster P, Pedersen J, Hedwards S, McPherson SJ, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/21674698
Molecular testing for paraffin embedded material. Pathology (2007). Gonzales M, Susman M, Dale S, Mills J – http://www.ncbi.nlm.nih.gov/pubmed/17886112
Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. Journal of Clinical Neurosciences (2006). Gonzales M, Dale S, Susman M, Mills J. http://www.ncbi.nlm.nih.gov/pubmed/16410204
Formation of human prostate tissue from embryonic stem cells. Nat Methods (2006). Taylor RA, Cowin PA, Cunha GR, Pera M, Trounson AO, Pedersen J, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/21674698
Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab (2004). Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP – http://www.ncbi.nlm.nih.gov/pubmed/15126575
Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology (2002). Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/12446620
Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev (2002). Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/12496063
Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Molecular Endocrinology (2002). Schmitt JF, Millar DS, Pedersen JS, Clark SL, Venter DJ, Frydenberg M, Molloy PL, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11818495
Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology (2001). McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11356695
Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab (2000). Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP. http://www.ncbi.nlm.nih.gov/pubmed/11134153